Clinical trials: Grade 3 Meningioma
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00363272
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Intracranial Meningioma
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
- Trial name
- MOMENTUM-1 (NCT06955169)
- Testing
- [177Lu]Lu-DOTATATE, Standard of Care treatments
- Where
- 17 sites in United States
- Volunteers
- 130 people
- Sponsor
- RTOG Foundation, Inc.
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00006246
- Testing
- busulfan
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain Tumors, Nervous System Tumors
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
RATIONALE: Armodafinil may help relieve fatigue and improve quality of life in patients with cancer receiving radiation therapy to the brain.
- Conditions
- Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
- Trial name
- NCT01032200
- Testing
- Armodafinil
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with…
- Trial name
- NCT00015899
- Testing
- lonafarnib
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pediatric Brain Tumor Consortium
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00053963
- Testing
- romidepsin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00994500
- Testing
- vorinostat, bortezomib, pharmacological study
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving high-dose radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- NCT00626730
- Testing
- adjuvant therapy, radiation therapy
- Where
- Switzerland
- Volunteers
- 78 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors, Sarcoma
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00348790
- Testing
- vatalanib
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors, Metastatic Cancer
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00784914
- Testing
- temsirolimus, pharmacological study, cytokine levels
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00020150
- Testing
- O6-benzylguanine, temozolomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
This phase I trial is studying the side effects and best dose of ABT-888 when given in combination with temozolomide in treating young patients with recurrent or refractory CNS tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00946335
- Testing
- veliparib, temozolomide, pharmacological study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Meningioma
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.
- Trial name
- NCT07533942
- Testing
- JZP3507
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Jazz Pharmaceuticals
Brain and Central Nervous System Tumors
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00360854
- Testing
- erlotinib hydrochloride, mutation analysis, polymorphism analysis
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Children's Cancer and Leukaemia Group
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Brain and Central Nervous System Tumors
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: SU5416 may stop the growth of brain cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the safety of delivering SU5416 in children who have recurrent or progressive brain tumors.
- Trial name
- NCT00006247
- Testing
- semaxanib
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pediatric Brain Tumor Consortium
Meningioma
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
Meningioma, the most common intracranial primary tumor of the central nervous system predominantly affects people in their fifties.
- Trial name
- ELUMEN (NCT06126588)
- Testing
- Everolimus
- Where
- 2 sites in France
- Volunteers
- 28 people
- Sponsor
- Central Hospital, Nancy, France
Meningioma
Abemaciclib in Newly Diagnosed Meningioma Patients
This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma.
- Trial name
- NCT05940493
- Testing
- Abemaciclib
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Nader Sanai
Brain and Central Nervous System Tumors
Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors
RATIONALE: Perfusion magnetic resonance imaging may be an effective method of measuring the growth of blood vessels in brain tumors. These measurements may help doctors better diagnose and treat brain tumors.
- Trial name
- NCT00005790
- Testing
- laboratory biomarker analysis, biopsy, magnetic resonance imaging
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors, Leukemia
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00458744
- Testing
- talotrexin, chemotherapy
- Sponsor
- Children's Oncology Group